High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Posted on 26 Jan 2026
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle to accurately assess clotting risk because standard tests focus on late stages of coagulation rather than its earliest triggers. Subtle changes in how easily blood begins to clot have therefore remained largely invisible in routine care. Researchers have now developed a blood test capable of detecting these early clotting differences, providing a more precise way to assess anticoagulant effects and disease-related abnormalities.
The high-sensitivity coagulation assay called SMAT has been developed by researchers at Kumamoto University (Kumamoto, Japan) to measure the very first generation of thrombin, a key enzyme that initiates clot formation. Unlike conventional clotting tests, SMAT captures thrombin activity through two specific pathways: the tissue factor–driven pathway and the FVIIIa/FIXa-dependent pathway, enabling pathway-specific assessment of coagulation dynamics.
The assay was evaluated in a large clinical study involving 771 patients with cardiovascular disease. Using SMAT, researchers quantified initial thrombin generation across both coagulation pathways and compared results among patients with different treatments and underlying conditions. The findings, published in Thrombosis and Haemostasis, showed that patients taking direct oral anticoagulants had markedly suppressed thrombin generation in both pathways. The test distinguished anticoagulant use with high accuracy, demonstrating its ability to objectively assess drug effectiveness.
In addition to medication effects, the assay revealed disease-specific clotting patterns. Patients undergoing dialysis showed reduced thrombin generation across both pathways, while chronic kidney disease and active cancer were associated with selective suppression of the tissue factor pathway. These nuanced differences are often missed by standard coagulation tests. The researchers suggest that pathway-specific thrombin profiles could support more personalized anticoagulant dosing, improved risk prediction, and a deeper understanding of clotting disorders across different diseases. Future studies will explore whether these early signals can be linked to long-term clinical outcomes.
“Our approach allows us to see the earliest spark of clot formation, rather than only the final outcome,” said Associate Professor Yuichiro Arima, lead investigator of the study. “This opens the door to more precise assessment of both clotting and bleeding risks, taking into account each patient’s medications and disease background.”
Related Links:
Kumamoto University
